Evidence map›Paper›PMID 38831415›Full record

ArticleImplementation science : IS2024

A data-driven approach to implementing the HPTN 094 complex intervention INTEGRA in local communities.

Laramie R Smith, Amaya Perez-Brumer, Melanie Nicholls, Jayla Harris, Qiana Allen, Alan Padilla, Autumn Yates, Eliza Samore, Rebecca Kennedy, Irene Kuo and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in Implementation science : IS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04804072 (INTEGRA), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04804072 nacompletednot on this map

INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons Who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care

TypeinterventionalSponsorHIV Prevention Trials NetworkRan2021 to 2024Enrolled447ConditionsHIV Infections, Drug Use, Opioid Use, Opioid-use DisorderArmsMedication for opioid-use disorder (MOUD) for opioid-use disorder (OUD), HIV testing, HIV treatment for participants living with HIV not already in care, PrEP for participants without HIV, Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Laramie R SmithSchool of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, CA, 92093-0507, USA. laramie@ucsd.edu.ORCID 0000-0002-5371-3229
Amaya Perez-BrumerDalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Melanie NichollsSchool of Social Work, San Diego State University, San Diego, USA.
Jayla HarrisHIV Prevention Trials Network, Family Health International 360, Durham, USA.
Qiana AllenUTHealth Houston McGovern School of Medicine, Houston, USA.
Alan PadillaColumbia University, ICAP, Mailman School of Public Health, New York, USA.
Autumn YatesGeorge Washington University Milken Institute School of Public Health, Washington, DC, USA.
Eliza SamoreCenter for Behavioral and Addiction Medicine at UCLA, Los Angeles, USA.
Rebecca KennedySchool of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, CA, 92093-0507, USA.
Irene KuoGeorge Washington University Milken Institute School of Public Health, Washington, DC, USA.
Jordan E LakeUTHealth Houston McGovern School of Medicine, Houston, USA.
Cecile DenisUniversity of Pennsylvania, Perelman School of Medicine, Philadelphia, USA.
David Goodman-MezaDivision of Infectious Diseases at UCLA, Los Angeles, USA.
Peter DavidsonSchool of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, CA, 92093-0507, USA.
Steve ShoptawDepartment of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA.
Nabila El-BasselSchool of Social Work, Columbia University, New York, USA.
HPTN 094 study protocol team

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
MassHEAL - Reducing overdose deaths by 40% (2019-2023)UM1DA049412 · NIDA · BOSTON MEDICAL CENTER · PI SAMET, JEFFREY H. · 2019 to 2023
$82.9M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
ICAP Clinical Trials UnitUM1AI154468 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WAFAA M. EL-SADR, JESSICA E. JUSTMAN · 2021 to 2026
$13.0M
The District of Columbia Clinical Trials Unit (DC CTU)UM1AI154466 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Sarah Henn, Manya Magnus · 2021 to 2026
$12.5M
NEXUS: A novel social network approach to study the effects of intersectional stigma on HIV prevention among Latino MSMR01MH123282 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, LARAMIE RAE · 2020 to 2024
$3.5M
Using data science to measure the impact of opioid agonist therapy in patients admitted with Staphylococcus aureus bloodstream infectionsK08DA048163 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOODMAN, DAVID · 2019 to 2023
$1.0M
CIHR CRC-2021-00132Division of Intramural Research, National Institute of Allergy and Infectious Diseases UM1AI068613-15Division of Intramural Research, National Institute of Allergy and Infectious Diseases UM1AI068617-15Division of Intramural Research, National Institute of Allergy and Infectious Diseases UM1AI068619-15Intramural Research Program, National Institute on Drug Abuse UM1DA049412NIAID NIH HHS P30 AI036214NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI154466NIAID NIH HHS UM1 AI154468NIDA NIH HHS K08 DA048163NIDA NIH HHS UM1 DA049412NIMH NIH HHS P30 MH058107NIMH NIH HHS R01 MH123282
6 · The paper itself

Abstract

backgroundHIV burden in the US among people who inject drugs (PWID) is driven by overlapping syndemic factors such as co-occurring health needs and environmental factors that synergize to produce worse health outcomes among PWID. This includes stigma, poverty, and limited healthcare access (e.g. medication to treat/prevent HIV and for opioid use disorder [MOUD]). Health services to address these complex needs, when they exist, are rarely located in proximity to each other or to the PWID who need them. Given the shifting drug use landscapes and geographic heterogeneity in the US, we evaluate a data-driven approach to guide the delivery of such services to PWID in local communities.

methodsWe used a hybrid, type I, embedded, mixed method, data-driven approach to identify and characterize viable implementation neighborhoods for the HPTN 094 complex intervention, delivering integrated MOUD and HIV treatment/prevention through a mobile unit to PWID across five US cities. Applying the PRISM framework, we triangulated geographic and observational pre-implementation phase data (epidemiological overdose and HIV surveillance data) with two years of implementation phase data (weekly ecological assessments, study protocol meetings) to characterize environmental factors that affected the viability of implementation neighborhoods over time and across diverse settings.

resultsNeighborhood-level drug use and geographic diversity alongside shifting socio-political factors (policing, surveillance, gentrification) differentially affected the utility of epidemiological data in identifying viable implementation neighborhoods across sites. In sites where PWID are more geographically dispersed, proximity to structural factors such as public transportation and spaces where PWID reside played a role in determining suitable implementation sites. The utility of leveraging additional data from local overdose and housing response systems to identify viable implementation neighborhoods was mixed.

conclusionsOur findings suggest that data-driven approaches provide a contextually relevant pragmatic strategy to guide the real-time implementation of integrated care models to better meet the needs of PWID and help inform the scale-up of such complex interventions. This work highlights the utility of implementation science methods that attend to the impact of local community environmental factors on the implementation of complex interventions to PWID across diverse drug use, sociopolitical, and geographic landscapes in the US.

trial registrationClincalTrials.gov, Registration Number: NCT04804072 . Registered 18 February 2021.

Indexed as

HIV InfectionsOpioid-Related DisordersSubstance Abuse, IntravenousDelivery of Health Care, IntegratedFemaleHealth Services AccessibilityHumansImplementation ScienceMaleResidence CharacteristicsSocial StigmaUnited StatesComplex interventionsHealth equityHIV preventionImplementation scienceIntegrated careMobile healthPeople who inject drugsPractical Robust Implementation Sustainability Model (PRISM)

Identifiers

PMID38831415
PMCPMC11149235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.